Skip to main content
Saurabh Dahiya on Muck Rack

Saurabh Dahiya

As seen in: Nature, Wiley Online Library, Healio, HemOnc Today, ONCOLOGY journal, OncLive, Campaign Middle East, CGTLive
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Saurabh

Contact Saurabh, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Dynamics of BCMA expression in patients with relapsed/refractory multiple myeloma receiving BCMA-directed CAR-T therapy

|
By Masooma Rana, Sebastian Fernandez-Pol, Alexandria M. Jensen, Arash Velayati, Jean S. Oak, Oscar Silva, Erik Ames, Lori Muffly, Bita Sahaf, Sally Arai, Vanessa Kennedy, Sushma Bharadwaj, David J. Iberri, Michaela Liedtke, Yasodha Natkunam, Parveen Shiraz, Wen-Kai Weng, Melody Smith, Matthew Frank, Crystal L. Mackall, Saurabh Dahiya, Lekha Mikkilineni, David Miklos, Hitomi Hosoya, Surbhi Sidana, Vanna Hovanky
| Nature Verified
Abstract There is limited systemic data on the dynamics of BCMA-target antigen expression with BCMA CAR-T at relapse. We analyzed 76 patients receiving standard-of-care BCMA-directed CAR-T who underwent real-time BCMA expression evaluation at baseline (n = 50), relapse (6), or both (20) using flow cytometry (FC) and/or immunohistochemistry (IHC). BCMA was universally expressed at baseline with significant heterogeneity in expression level.
Open in Who Shared Issue with article?

Omotayo Fasan, MRCP, DTM&H, MBBS, on Evaluating CAR-T GLPG5101 in R/R NHL

|
By Saurabh Dahiya, Noah Stansfield, Ashling Wahner Verified, Caroline Seymour
| CGTLive
At the European Hematology Association (EHA) 2025 Congress, held June 12 to 15, both virtually and in Milan, Italy, Galapagos presented new data regarding GLPG5101, an investigational. CD19-directed chimeric antigen receptor T-cell (CAR-T) therapy product. During the conference, CGTLive® interviewed Omotayo Fasan, MRCP, DTM&H, MBBS, the head of the clinical development program at Galapagos, about the findings.
Open in Who Shared Issue with article?

CAR-T KITE-363's Safety Profile in R/R B-Cell Lymphoma

|
By Saurabh Dahiya, Noah Stansfield, Ashling Wahner Verified, Caroline Seymour
| CGTLive
At the European Hematology Association (EHA) 2025 Congress, held June 12 to 15, both virtually and in Milan, Italy, data are being presented from a phase 1 clinical trial (NCT04989803) evaluating Kite's KITE-363, a dual CD19 and CD20-directed chimeric antigen receptor (CAR) T-cell therapy, for the treatment of patients with relapsed/refractory (r/r) B-cell lymphoma.
Open in Who Shared View Duplicates (4) Issue with article?
See all 21 licensed articles (29 Total)